TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19817885
Drug: 27 tablets
Normalized name: RED 27
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 tablets of 10 mg rizatriptan ODT per month
Study: 19817885
Drug: 9 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 tablets of 10 mg rizatriptan ODT per month
Study: 17766654
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy for women with endocrine-responsive disease
Study: 17766654
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for postmenopausal women with endocrine nonresponsive early breast cancer
Study: 15001822
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 178 mg
Study: 15001822
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion (BUP) 150 mg
Study: 11443512
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day plus psyllium mucilloid 6.0 g
Study: 11443512
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day plus placebo
Study: 11443512
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus orlistat 120 mg three times a day
Study: 11443512
Drug: Psyllium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium plus orlistat 120 mg three times a day
Study: 8231168
Drug: HSV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV with patch
Study: 8231168
Drug: Control (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (subcutaneous infusion of pentagastrin and carbachol)
Study: 3306780
Drug: Calf lung
Normalized name: Calf lung surfactant extract (CLSE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf lung surfactant extract (CLSE) 90 mg by intratracheal instillation
Study: 29395119
Drug: Ranibizumab (RBZ)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP)
Study: 29395119
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) monotherapy
Study: 23088936
Drug: Intravenous nifekalant
Normalized name: Nifekalant
DrugBank: Nifekalant (DB16008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nifekalant (0.3mg/kg)
Study: 23088936
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous nifekalant (no-AAD group)
Study: 21406472
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus trastuzumab (L+T)
Study: 21406472
Drug: Single-agent lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent lapatinib (L)
Study: 16431307
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical treatment (biofeedback training and/or laxative treatment)
Study: 8646485
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and HSCT (specific regimens not detailed)
Study: 24075485
Drug: Sivelestat (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.2 mg/kg per hour)
Study: 17223855
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily for 2 days
Study: 17223855
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice 200 ml three times daily for 2 days
Study: 15452189
Drug: Cognitive-existential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-existential group therapy (CEGT) with 20 sessions of weekly group therapy plus three relaxation classes (n = 154)
Study: 12106752
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) 50 mg plus placebo pill/day
Study: 12106752
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg plus placebo pill/day
Study: 12106752
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) 50 mg plus vitamin C 500 mg/day
Study: 12106752
Drug: 2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo pills/day (control)
Study: 8529731
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic cisplatin, methotrexate and vinblastine chemotherapy
Study: 2311149
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg.kg‐1 (single dose)
Study: 2311149
Drug: Edrophonium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.2 mg.kg‐1 followed by 0.8 mg.kg‐1 (divided doses)
Study: 367874
Drug: Glucagon (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (administered intramuscularly and intravenously)
Study: 6832198
Drug: Alinidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (0.5 mg/kg i.v.)
Study: 26324738
Drug: Cixutumumab 10
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 10 mg/kg and the same antiestrogen (arm A)
Study: 26324738
Drug: Cixutumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (10 mg/kg) with or without antiestrogen
Study: 26324738
Drug: Lower IR-A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower IR-A, IR-B, and total IR mRNA expression in tumor tissue (regardless of treatment)
Study: 11244227
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (Daivonex/Dovonex) used daily combined with UVB treatments twice weekly
Study: 11244227
Drug: Emollient used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient used daily combined with UVB treatments three times weekly
Study: 22014603
Drug: Variable dosing
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dosing of intravitreal bevacizumab (1.25 mg/0.05 mL)
Study: 22014603
Drug: Fixed-interval dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-interval dosing of intravitreal bevacizumab (every 4 to 6 weeks)
Study: 20577706
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine patches (LP) as an add-on to established pain medication
Study: 20577706
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine patches (LP)
Study: 17498072
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with rFVIIa and APCC
Study: 11756906
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution injection (1‐2 mL boluses; mean volume 30 mL)
Study: 11756906
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution injection
Study: 7979927
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (progressive interval training with bicycle exercises, heel lifts, and step-climbing, performed twice weekly for 45 minutes over 3 months)
Study: 28927673
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 to 60 mg/day for 14 days)
Study: 22045924
Drug: DPP4 inhibitor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP4 inhibitor, sitagliptin
Study: 20191713
Drug: Comparison treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatments
Study: 9449907
Drug: 0.5% podofilox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podofilox gel
Study: 7637723
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg per day)
Study: 2699466
Drug: Doxofylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline (400 mg twice daily)
Study: 2699466
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline (300 mg twice daily)
Study: 31236888
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of oral DKP daily (Group A)
Study: 31236888
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Diane‐35 orally daily (Group B)
Study: 31236888
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of oral DKP daily plus 1 tablet of Diane‐35 orally daily (Group C)
Study: 23378417
Drug: Cholecalciferol (25,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (25,000 IU) therapy every 2 weeks
Study: 20188537
Drug: Dynamic Conformal
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic Conformal Arc Therapy (DCAT)
Study: 17595892
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg i.v. (administered over 30 min)
Study: 17595892
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg i.v. (administered over 30 min)
Study: 17595892
Drug: Esomeprazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Study: 17595892
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Study: 15077462
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with loperamide 2‐6 mg/day for 2 months
Study: 9707184
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy before randomization (tPA 9%, placebo 9%)
Study: 9707184
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy after randomization (tPA 24%, placebo 29%)
Study: 9707184
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy after randomization for tPA patients
Study: 21159021
Drug: 1 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg·kg(‐1) of clonidine
Study: 21159021
Drug: 2 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg·kg(‐1) of clonidine
Study: 21159021
Drug: 3 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg·kg(‐1) of clonidine
Study: 15086603
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy (EIS) (13 patients; group B)
Study: 11232676
Drug: 1-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Study: 11232676
Drug: 2-week treatment
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Study: 8607560
Drug: FPANS 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPANS 200 micrograms twice daily (bd)
Study: 8607560
Drug: FPANS 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPANS 200 micrograms once daily (od)
Study: 1071608
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment with metolazone or hydrochlorothiazide
Study: 1071608
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (before treatment)
Study: 30474376
Drug: Multilevel church-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel church-based intervention including sermons, educational handouts, vegetable and fruit gardens, cooking and nutrition classes, daily mobile messaging, community mapping, and policy changes over 5 months.
Study: 24897394
Drug: Oxytocin administered
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administered after placenta separation (Group 1)
Study: 24897394
Drug: Oxytocin administered
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administered after delivery of the shoulder (Group 2)
Study: 19575235
Drug: Toltrazuril (Baycox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toltrazuril (Baycox 5% suspension)
Study: 18396608
Drug: Pre-packaging antimalarial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-packaging antimalarial drugs and counselling
Study: 11798728
Drug: H(2) strain
Normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H(2) strain vaccine
Study: 7950211
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) and Traditional Chinese Medicine (TCM)
Study: 7950211
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with same western medicine but no TCM
Study: 2906458
Drug: Roxatidine acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate, 75 mg twice daily
Study: 2906458
Drug: Roxatidine acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate, 150 mg at bedtime
Study: 2906458
Drug: Roxatidine acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate, 150 mg after evening meal
Study: 25837277
Drug: Sertraline vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline vs Placebo
Study: 23295630
Drug: Short-term supportive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term supportive psychodynamic therapy (PDT)
Study: 23295630
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PDT + Antidepressants)
Study: 19221060
Drug: 3D ultrasonography
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D ultrasonography (US) enhanced with a perflubutane microbubble contrast agent
Study: 16536197
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop (3M ESPE)
Study: 10690389
Drug: Melphalan 8
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 8 mg/m2/d x 4 weeks x 18 courses
Study: 8438599
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) and Molsidomine (ML)
Study: 3887254
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of trimethoprim
Study: 3887254
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of co-trimoxazole
Study: 26725450
Drug: High-dose vaccine
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaccine (5×10^10 viral particles)
Study: 26725450
Drug: Low-dose vaccine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaccine (2.5×10^10 viral particles)
Study: 24431901
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of autologous bone marrow-derived mesenchymal stem cells (MSCs)
Study: 18251758
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 0.1 mg imidafenacin
Study: 18251758
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.028 mg imidafenacin
Study: 16855626
Drug: Two classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two classes of antihypertensive medication
Study: 16855626
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more classes of antihypertensive medication
Study: 16855626
Drug: Doctor diagnosis
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor diagnosis of hypertension and taking antihypertensive medication
Study: 9082840
Drug: Innogem (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innogem (300 mg)
Study: 9082840
Drug: Lopid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopid (300 mg)
Study: 1900977
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue‐type plasminogen activator (100 mg over 3 hours, group A)
Study: 1900977
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (group B)
Study: 7011469
Drug: sulpiride (600-1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulpiride (600-1,800 mg/day)
Study: 7011469
Drug: trifluoperazine (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: trifluoperazine (15-45 mg/day)
Study: 25869815
Drug: Naftopidil (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (75 mg once in the morning and placebo twice a day)
Study: 25869815
Drug: Flopropione (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flopropione (80 mg three times a day)
Study: 24005170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no salvage therapies)
Study: 20601033
Drug: Initial systemic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial systemic treatment for cGVHD
Study: 11333843
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg x kg(‐1) x d(‐1) lysine intake
Study: 11333843
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg x kg(‐1) x d(‐1) lysine intake
Study: 11333843
Drug: 28 mg
Normalized name: aspirin 228 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 mg x kg(‐1) x d(‐1) lysine intake
Study: 11333843
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg x kg(‐1) x d(‐1) lysine intake
Study: 3113290
Drug: Epidural morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine, 4 mg
Study: 3113290
Drug: Epidural buprenorphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine, 0.15 mg
Study: 3113290
Drug: Epidural buprenorphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine, 0.3 mg
Study: 27318048
Drug: High ligation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ligation and stripping with and without patch saphenoplasty
Study: 26040543
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (RG) - complex multi-method rehabilitation intervention including structured education, cognitive behavioral therapy (CBT), progressive individualized exercise, and peer support.
Study: 16189255
Drug: Depot estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot estradiol, 0.2 mg/month i.m. with GH 0.05 mg/kg daily
Study: 10658893
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT, n = 30)
Study: 8841871
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of allopurinol 18 hours and 400 mg of allopurinol orally 3 hours before surgery
Study: 1632701
Drug: Intradermal OK-432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal OK-432
Study: 1632701
Drug: Oral OK-432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OK-432 with preserved spleen
Study: 6499513
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam twice-daily for 3 days
Study: 6499513
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam twice-daily for 7 days
Study: 21340661
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days
Study: 21340661
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin qd for 11 days
Study: 12544367
Drug: Notoginseny cream
Normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Notoginseny cream
Study: 12544367
Drug: Hirudoid cream
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudoid cream (Control)
Study: 10787394
Drug: Acamprosate 666
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 666 mg three times/day
Study: 1626496
Drug: Colestipol 5
Normalized name: colestipol 5 g oral granule for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 5 g/day
Study: 1626496
Drug: Colestipol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 10 g/day
Study: 1626496
Drug: Colestipol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 15 g/day
Study: 27852965
Drug: D-cycloserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (100 mg, 200 mg, and 400 mg for two weeks each)
Study: 24937016
Drug: Enhanced intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced intervention (monthly counseling phone calls, weekly mailings with tailored and non-tailored materials, videos)
Study: 22100204
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of misoprostol sublingually
Study: 12374540
Drug: rhIL-10 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-10 (20 micro g/kg) subcutaneously 3 times weekly for 12 weeks
Study: 12374540
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously 3 times weekly for 12 weeks
Study: 2106162
Drug: Ifosfamide 2
Normalized name: ifosfamide 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection
Study: 2106162
Drug: Doxorubicin, ifosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin, ifosfamide, dacarbazine at doses of 60, 7,500, and 900 mg/m2 respectively by continuous infusion over 72 hours